AURORA, Ontario, Nov. 25 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") has filed a Form 20-F Registration Statement with the United States Securities and Exchange Commission, to register its common shares with the SEC.
A Form 20-F, once declared effective by the SEC, allows certain foreign corporations to register securities with the SEC pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. The Company's Form 20-F is a full registration of the Company's common shares with the SEC as a foreign private issuer similar to a Form 10 filing for a domestic issuer in the United States. The Company's registration of its shares in the United States would allow its shares to be solicited and traded by licensed brokers in the United States in compliance with SEC regulations and blue sky requirements in various states in the United States.
"Today's filing is a significant step for the Company toward our goal to enter larger capital markets," said John Docherty, president of Helix BioPharma. "Following effectiveness, we intend to expand our ongoing efforts to grow Helix's corporate profile, with a view to broadening our U.S. investor base and increasing our liquidity."
The Form 20-F is being filed on EDGAR and SEDAR at www.sec.gov/edgar.shtml and www.sedar.com, respectively. Helix anticipates the Form 20-F will be declared effective by the SEC in early 2009, although there is no guarantee that the SEC will declare the filing effective. If the Form 20-F is declared effective by the SEC, the Company will be obligated to file continuous disclosure documentation applicable to foreign private issuers with the SEC following the date the Form 20-F is declared effective.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmac
|SOURCE Helix BioPharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved